APSR2026-698

Yes
Late-Breaking
Submitted
Oral Presentation
AO20-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1220895-46903-APSR-APSR2026-698_440639.pptx
Format: PPTX Only
 
Format: PDF Only
15. Pulmonary Circulation
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Sagita Mega Sekar Kencana * Kobe University Graduate School of Medicine/Department of Internal Medicine/Division of Cardiovascular Medicine Kobe Japan
Gusty Rizky Teguh Ryanto - Kobe Pharmaceutical University Laboratory of Clinical Pharmaceutical Science Kobe Japan
Novia Nurul Faizah - Kobe University Graduate School of Medicine/Department of Internal Medicine/Division of Cardiovascular Medicine Kobe Japan
Yoko Suzuki - Kobe Pharmaceutical University Laboratory of Clinical Pharmaceutical Science Kobe Japan
Tetsuya Hara - Kobe Pharmaceutical University Laboratory of Clinical Pharmaceutical Science Kobe Japan
Hiromasa Otake - Kobe University Graduate School of Medicine/Department of Internal Medicine/Division of Cardiovascular Medicine Kobe Japan
Noriaki Emoto - Kobe Pharmaceutical University Laboratory of Clinical Pharmaceutical Science Kobe Japan
 
 
 
 
 
 
 
 
Presenting Author Details
Sagita Mega Sekar
Kencana
sagitamegask@gmail.com
+818023099096
31-40
Japan
Original Research
Explaining the rationale of targeting Activin A to treat Pulmonary Hypertension in COPD
Maximum 25 words
Abstract Content
Pulmonary hypertension (PH) is a frequent complication in chronic obstructive pulmonary disease (COPD) that increases its morbidity and mortality rate. Unfortunately, there are no clinically approved therapies that can specifically target PH associated with COPD (COPD-PH). The pathogenesis of COPD-PH is linked to hypoxia-driven vascular remodeling. We previously showed how endothelial Activin A, a TGF-β superfamily protein encoded by the gene INHBA, is induced by acute hypoxia, and its inhibitor, sotatercept, is clinically effective in treating a different form of PH (pulmonary arterial hypertension/PAH). Still, its role in hypoxia-driven COPD-PH remains unclear. Thus, we investigated the role of Activin A in COPD-PH.
To confirm the regulation of endothelial activin A during chronic hypoxia condition such as in COPD-PH, we exposed human pulmonary artery endothelial cells (PAEC) to chronic hypoxia (5% O2, 72 hours) with HIF-1 inhibitor (FM19G11) or HIF-2 inhibitor (PT2385) in vitro. We also isolated mouse lung ECs from intratracheal elastase-treated COPD-PH model wild-type (WT) mice or vehicle-treated to confirm similar changes in activin A. To confirm the role of EC activin A in promoting COPD-PH, we treated EC-specific INHBA knock-out (INHBA-ECKO) mice with intratracheal elastase and assessed their lung parenchymal and vascular functional, hemodynamic, histological, and molecular phenotype after 28 days of instillation.
The hypoxia-driven INHBA increase was reduced after inhibiting HIFs, especially after HIF-2 inhibition. A similar increase in EC INHBA/Activin A level was found after elastase instillation, with concurrent increase in both HIF-1α and HIF-2α. Interestingly, INHBA-ECKO mice showed improved PH phenotype (reduced right ventricular systolic pressure, Fulton index, and vascular remodeling) without affecting lung function and structure compared to WT mice.
We identified that activin A mediates hypoxia-induced vascular remodeling in COPD-PH without affecting the underlying lung disease, highlighting the potential of inhibiting activin A as a COPD-PH-specific therapy.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
activin A, COPD, pulmonary hypertension
maximum 3 keywords and no abbreviations, separated by commas
We have nothing to disclose.
296